Cargando…

Multidrug-resistant tuberculosis in COVID-19: Double trouble

COVID-19 pandemic has changed the lives of many especially those living with chronic diseases. India has the highest burden of multidrug resistant tuberculosis (MDR TB) in the world. The pandemic and the lockdown created multiple bottlenecks in the provision of healthcare as well as the distribution...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwah, Vikas, Peter, Deepu K., Ajai Kumar, Tentu, Bhati, Gaurav, Kumar, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313087/
https://www.ncbi.nlm.nih.gov/pubmed/34334915
http://dx.doi.org/10.1016/j.mjafi.2021.05.002
_version_ 1783729268513046528
author Marwah, Vikas
Peter, Deepu K.
Ajai Kumar, Tentu
Bhati, Gaurav
Kumar, Arvind
author_facet Marwah, Vikas
Peter, Deepu K.
Ajai Kumar, Tentu
Bhati, Gaurav
Kumar, Arvind
author_sort Marwah, Vikas
collection PubMed
description COVID-19 pandemic has changed the lives of many especially those living with chronic diseases. India has the highest burden of multidrug resistant tuberculosis (MDR TB) in the world. The pandemic and the lockdown created multiple bottlenecks in the provision of healthcare as well as the distribution of medications. The stigma of tuberculosis leads to mental trauma, suffering, delay in diagnosis, and non-compliance to therapy. Lockdown imposed due to COVID-19, aggravated the fears of each patient and had made medical care access difficult. Here we describe a patient with MDR TB and chronic hepatitis B and how the course of the disease and its management was affected by COVID-19.
format Online
Article
Text
id pubmed-8313087
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83130872021-07-26 Multidrug-resistant tuberculosis in COVID-19: Double trouble Marwah, Vikas Peter, Deepu K. Ajai Kumar, Tentu Bhati, Gaurav Kumar, Arvind Med J Armed Forces India Case Report COVID-19 pandemic has changed the lives of many especially those living with chronic diseases. India has the highest burden of multidrug resistant tuberculosis (MDR TB) in the world. The pandemic and the lockdown created multiple bottlenecks in the provision of healthcare as well as the distribution of medications. The stigma of tuberculosis leads to mental trauma, suffering, delay in diagnosis, and non-compliance to therapy. Lockdown imposed due to COVID-19, aggravated the fears of each patient and had made medical care access difficult. Here we describe a patient with MDR TB and chronic hepatitis B and how the course of the disease and its management was affected by COVID-19. Elsevier 2021-07 2021-07-26 /pmc/articles/PMC8313087/ /pubmed/34334915 http://dx.doi.org/10.1016/j.mjafi.2021.05.002 Text en © 2021 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.
spellingShingle Case Report
Marwah, Vikas
Peter, Deepu K.
Ajai Kumar, Tentu
Bhati, Gaurav
Kumar, Arvind
Multidrug-resistant tuberculosis in COVID-19: Double trouble
title Multidrug-resistant tuberculosis in COVID-19: Double trouble
title_full Multidrug-resistant tuberculosis in COVID-19: Double trouble
title_fullStr Multidrug-resistant tuberculosis in COVID-19: Double trouble
title_full_unstemmed Multidrug-resistant tuberculosis in COVID-19: Double trouble
title_short Multidrug-resistant tuberculosis in COVID-19: Double trouble
title_sort multidrug-resistant tuberculosis in covid-19: double trouble
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313087/
https://www.ncbi.nlm.nih.gov/pubmed/34334915
http://dx.doi.org/10.1016/j.mjafi.2021.05.002
work_keys_str_mv AT marwahvikas multidrugresistanttuberculosisincovid19doubletrouble
AT peterdeepuk multidrugresistanttuberculosisincovid19doubletrouble
AT ajaikumartentu multidrugresistanttuberculosisincovid19doubletrouble
AT bhatigaurav multidrugresistanttuberculosisincovid19doubletrouble
AT kumararvind multidrugresistanttuberculosisincovid19doubletrouble